This report investigated in vivo turnover kinetics of marrow hematopoietic progenitors and precursors using a recently developed stable isotope-mass spectrometric technique (SIMST). Human subjects were administered a 2-day infusion of 6,6-[2H2]-glucose, a nontoxic stable isotope-labeled form of glucose, which becomes incorporated into DNA of all S-phase cells. The percent [2H2]-glucose incorpor...

PURPOSE In CD34-positive acute myeloid leukemia (AML), the leukemia-initiating event originates from the CD34(+)CD38(-) stem cell compartment. Survival of these cells after chemotherapy may lead to minimal residual disease (MRD) and subsequently to relapse. Therefore, the prognostic impact of stem cell frequency in CD34-positive AML was investigated. EXPERIMENTAL DESIGN First, the leukemogeni...

CD34(+)-selected hematopoietic progenitor cells are being increasingly used for autotransplantation, and recent evidence indicates that these cells can be expanded ex vivo. Of 15 patients with solid tumors undergoing a phase I/II clinical trial using CD34(+)-selected peripheral blood progenitor cells (PBPCs) after high-dose chemotherapy, we analyzed the frequency of long-term culture-initiating...

This report investigated in vivo turnover kinetics of marrow hematopoietic progenitors and precursors using a recently developed stable isotope–mass spectrometric technique (SIMST). Human subjects were administered a 2-day infusion of 6,6-[H2]-glucose, a nontoxic stable isotope-labeled form of glucose, which becomes incorporated into DNA of all Sphase cells. The percent [H2]-glucose incorporate...

Objective—The presence of kinase-insert domain-containing receptor (KDR) on circulating CD34 cells is assumed to be indicative for the potential of these cells to support vascular maintenance and repair. However, in bone marrow and in granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood, less than 0.5% of CD34 cells co-express KDR. Therefore, we studied whether CD34 /KDR cel...

OBJECTIVE The presence of kinase-insert domain-containing receptor (KDR) on circulating CD34+ cells is assumed to be indicative for the potential of these cells to support vascular maintenance and repair. However, in bone marrow and in granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood, less than 0.5% of CD34+ cells co-express KDR. Therefore, we studied whether CD34+/KDR+ ...

background: human cd34 is a transmembrane glycoprotein which is expressed in human hematopoietic stem cells (hscs) and the small- vessel endothelial cells of a variety of tissues. cd34 plays a critical role as a marker for diagnosis and classification of leukemia. anti cd34 antibodies are used for isolation and purification of hscs from bone marrow, peripheral blood and cord blood. objective: t...

The replacement of bone marrow (BM) as a conventional source of stem cell (SC) by umbilical cord blood (UCB) and granulocyte-colony stimulating factor-mobilized peripheral blood SC (PBSC) has brought about clinical advantages. However, several studies have demonstrated that UCB CD34(+) cells and PBSC significantly differ from BM CD34(+) cells qualitatively and quantitatively. Here, we quantifie...

The use of ex vivo expanded CD34-selected hematopoietic progenitor cells (HPCs) for autologous stem cell support or gene therapy is a major area of research and is likely to increase in the future. At present, little is known about the fate of contaminating malignant cells during ex vivo expansion of CD34-selected HPCs. We established a competitive polymerase chain reaction (PCR) titration assa...

In skin, IL-9 is best known as a key cytokine in contact dermatitis. Yet, we noted that its receptor (IL-9R) was also expressed the hair follicle (HF) epithelium. Therefore, asked whether IL-9R-mediated signaling modulated human HF growth and/or immune status. To address this, full-length healthy scalp HFs were organ-cultured presence/absence of recombinant (rh) for six days. Quantitative (immu...